Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis
Metrics: PDF 538 views | HTML 990 views | ?
Jingfeng Bi1,*, Zheng Zhang1,*, Enqiang Qin2,*, Jun Hou1,*, Shuiwen Liu3, Zengmin Liu4, Shuo Li3, Zhenman Wei1 and Yanwei Zhong5
1Research Center for Clinical and Translational Medicine, 302 Hospital, Beijing, 100039, China
2Infectious Disease Treatment Center, 302 Hospital, Beijing, 100039, China
3Medical Department, 302 Hospital, Beijing, 100039, China
4Medical Department, XingLong Hospital of TCM, Beijing, 100039, China
5Institute of Infectious Disease, Pediatric Liver Disease Therapy and Research Center, 302 Hospital, Beijing, 100039, China
*These authors contributed equally to this work
Zhenman Wei, email: firstname.lastname@example.org
Yanwei Zhong, email: email@example.com
Keywords: nucleoside analogs, hepatitis B, cirrhosis, hepatocellular carcinoma
Received: April 07, 2017 Accepted: May 06, 2017 Published: May 22, 2017
Whether Nucleos(t)ide analogs(NA) treatment can delay the onset of HCC remains unclear. We retrospectively analyzed the clinical data of patients with HBV-related cirrhosis and HCC from 2000 to 2012. Cox proportional hazards model was used to explore the association between NA treatment and postponement of HCC development, the dependent variable was time interval from cirrhosis treatment towards the onset of HCC, and the covariates included age, sex, family history, compensation status at baseline. A total of 1155 HCC patients treated with NAs (n = 528, lamivudine, adefovir, entecavir) and non NA (n = 627) for more than 24 months before the occurrence of HCC were incorporated into the cohort. Compared with the non-NA group, NAs therapy was associated with delaying the onset of HCC in patients with cirrhosis. Significant factors were: adefovir treatment (n = 181; p = 0.0072; HR: 0.792; 90% CI: 0.687–0.914), entecavir treatment (n = 83; p = 0.0068; HR: 0.716; 90% CI: 0.585-0.877), lamivudine switched to adefovir treatment (n = 95, p = 0.0808; HR: 0.822; 90% CI: 0.684 to 0.989). But Lamivudine monotherapy was not a significant factor (n = 102; p = 0.6877; HR: 1.045; 90% CI: 0.873–1.250). Long-term NA treatment (> 6 months, except for lamivudine monotherapy) can delay the onset of HCC in patients with HBV-related cirrhosis, and applying high barrier NA to resistance is important in these patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.